Natixis Advisors LLC Purchases 11,870 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Natixis Advisors LLC grew its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 36.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 44,346 shares of the company's stock after buying an additional 11,870 shares during the quarter. Natixis Advisors LLC owned 0.06% of Crinetics Pharmaceuticals worth $2,266,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. AQR Capital Management LLC increased its holdings in Crinetics Pharmaceuticals by 3.3% during the second quarter. AQR Capital Management LLC now owns 7,126 shares of the company's stock worth $319,000 after buying an additional 227 shares during the last quarter. US Bancorp DE increased its stake in shares of Crinetics Pharmaceuticals by 3.4% during the 3rd quarter. US Bancorp DE now owns 11,488 shares of the company's stock worth $587,000 after purchasing an additional 373 shares during the last quarter. KBC Group NV increased its stake in shares of Crinetics Pharmaceuticals by 22.8% during the 3rd quarter. KBC Group NV now owns 2,193 shares of the company's stock worth $112,000 after purchasing an additional 407 shares during the last quarter. Amalgamated Bank raised its holdings in shares of Crinetics Pharmaceuticals by 20.8% in the 2nd quarter. Amalgamated Bank now owns 2,692 shares of the company's stock worth $121,000 after purchasing an additional 464 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Crinetics Pharmaceuticals by 23.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company's stock valued at $147,000 after purchasing an additional 541 shares during the last quarter. Hedge funds and other institutional investors own 98.51% of the company's stock.

Analyst Ratings Changes

CRNX has been the subject of a number of recent research reports. HC Wainwright raised their target price on Crinetics Pharmaceuticals from $69.00 to $81.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Citigroup lifted their price objective on Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a "buy" rating in a report on Thursday, November 14th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $90.00 price objective on shares of Crinetics Pharmaceuticals in a report on Monday, September 16th. JMP Securities reiterated a "market outperform" rating and issued a $80.00 target price on shares of Crinetics Pharmaceuticals in a research note on Friday, September 27th. Finally, Oppenheimer restated an "outperform" rating and set a $73.00 price target (down from $74.00) on shares of Crinetics Pharmaceuticals in a research note on Friday, August 9th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Crinetics Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $70.18.

Insiders Place Their Bets

In related news, insider Dana Pizzuti sold 14,375 shares of the stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $54.63, for a total transaction of $785,306.25. Following the transaction, the insider now owns 28,507 shares of the company's stock, valued at approximately $1,557,337.41. This trade represents a 33.52 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stephen F. Betz sold 1,035 shares of the company's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $51.50, for a total transaction of $53,302.50. Following the sale, the insider now owns 68,576 shares of the company's stock, valued at approximately $3,531,664. The trade was a 1.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,410 shares of company stock valued at $2,116,359 over the last 90 days. Insiders own 6.00% of the company's stock.

Crinetics Pharmaceuticals Trading Up 0.1 %

Shares of Crinetics Pharmaceuticals stock traded up $0.03 during trading on Monday, hitting $56.09. The stock had a trading volume of 580,897 shares, compared to its average volume of 782,989. The firm has a market cap of $5.20 billion, a price-to-earnings ratio of -15.04 and a beta of 0.62. Crinetics Pharmaceuticals, Inc. has a 12 month low of $30.87 and a 12 month high of $62.53. The business's 50-day moving average is $55.36 and its 200 day moving average is $51.60.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.05). During the same quarter in the previous year, the firm posted ($1.01) EPS. As a group, equities analysts expect that Crinetics Pharmaceuticals, Inc. will post -3.75 EPS for the current year.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.